Small companies bring to the table a range of advantages over large ones when it comes to rare diseases, according to Ovid CEO Jeremy Levin. But he’s learned the hard way that it doesn’t help to innovate around endpoints if you can’t explain your strategy to investors.
As the company gears up for its first Phase III trial, Levin is focusing on three areas he sees as crucial for rare neurological diseases -- patient outreach, endpoints and collaborations -- as well as avoiding the missteps made in the Phase II trial.
Levin joined Ovid Therapeutics Inc. in 2015, bringing the fledgling biotech more than a decade of senior leadership experience in big pharma, and expertise in strategic alliances. Levin also is chair of BIO, a position he took up in June (see “Levitating Levin”).
In his career, he served as global head of strategic alliances at Novartis Institutes for Biomedical Research Inc., held several positions at Bristol-Myers Squibb Co. including SVP of strategy, alliances and transactions, and more recently was president